Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
veglin
- Development stage
- Discontinued
- Lead developer
- Vasgene Therapeutics
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Veglin is an investigational antisense oligonucleotide designed to inhibit the production of vascular endothelial growth factors (VEGF), which are proteins essential for angiogenesis—the formation of new blood vessels. By binding to DNA sequences responsible for encoding VEGF proteins, Veglin blocks their synthesis and thereby restricts the blood supply necessary for tumor growth and metastasis. Developed by VasGene Therapeutics in collaboration with researchers at the University of Southern California, Veglin was intended as a non-chemotherapy anti-angiogenic therapy for various malignancies including mesothelioma, Kaposi's sarcoma, renal cancer, and other solid tumors. Its mechanism involves antagonism of multiple vascular endothelial growth factor receptors (VEGFR-1/2/3). Clinical trials demonstrated some efficacy in reducing or stabilizing tumor burden; however, development has been discontinued across all indications[1][2][3][4][7].
- Brand names
- Veglin
- Other names
- VeglinVEGF-ASVEGF antisense oligonucleotide
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFA (Vascular endothelial growth factor A)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on veglin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veglin.